In pancreatic cancer, the epidermal growth factor receptor (EGFR) is expressed in 30–90% of patients with pancreatic ductal adenocarcinoma (PDAC)4–6, marking aggressive disease with poor survival rates. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.